EFFICACY OF AZACITIDINE TO RESTORE FULL DONOR CHIMERISM IN MDS OR AML PATIENTS AFTER ALLOGENEIC HSCT: A THERAPEUTIC OPTION FOR TREATMENT OF EARLY RELAPSE

被引：0
|
作者：
Gozzini, A. [1 ]
Guidi, S. [1 ]
Nozzoli, C. [1 ]
Saccardi, R. [1 ]
Santini, V. [2 ]
Donnini, I. [1 ]
Angarano, R. [1 ]
Boncompagni, R. [1 ]
Sanna, A. [1 ]
Bosi, A. [2 ]
机构：
[1] Univ Florence, Hematol, AOU CAREGGI, Florence, Italy
[2] Univ Florence, Hematol, Florence, Italy
来源：
BONE MARROW TRANSPLANTATION | 2014年 / 49卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
PH-P171
引用
收藏
页码：S182 / S182
页数：1
相关论文
共 50 条
  • [41] Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS
    Najima, Yuho
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 118 (02) : 169 - 182
  • [42] Characterization of lineages specific chimerism in patients with acute leukemia and MDS after allogeneic SCT before and after relapse.
    Bader, P
    Stoll, K
    Huber, S
    Geiselhart, A
    Handgretinger, R
    Niemeyer, C
    Einsele, H
    Hebarth, H
    Niethammer, D
    Beck, J
    Klingebiel, T
    BONE MARROW TRANSPLANTATION, 1999, 23 : S48 - S48
  • [43] Low-Dose Azacitidine (AZA) for Treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapse after Allogeneic Hematopoietic Cell Transplant (HCT)
    Ueda, Masumi
    Lazarus, Hillard M.
    Cooper, Brenda
    Caimi, Paolo
    Creger, Richard
    Little, Jane A.
    Baer, Linda
    Brister, Lauren
    Malek, Ehsan
    Metheny, Leland, III
    Tomlinson, Benjamin
    Gerson, Stan L.
    Oran, Betul
    de Lima, Marcos
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S212 - S213
  • [44] Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS
    Yuho Najima
    International Journal of Hematology, 2023, 118 : 169 - 182
  • [45] Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Final Results of the Prospective Azalena-Trial (NCT02472690
    Schroeder, Thomas
    Stelljes, Matthias
    Chirstopeit, Maximilian
    Schmidt, Eva
    Scheid, Christoph
    Mikesch, Jan-Henrik
    Rautenberg, Christina
    Jaeger, Paul
    Drusenheimer, Nadja
    Holtick, Udo
    Klein, Stefan
    Trenschel, Rudolf
    Haas, Rainer
    Germing, Ulrich
    Kroeger, Nicolaus
    Kobbe, Guido
    BLOOD, 2021, 138
  • [46] Treatment of Relapsed AML and MDS After Allogeneic Stem Cell Transplantation: A Second Transplant From a Different Donor May Be the Most Effective Option
    Shimoni, Avichai
    Shem-Tov, Noga
    Volchek, Yulia
    Yerushalmi, Ronit
    Nagler, Arnon
    BLOOD, 2012, 120 (21)
  • [47] Efficacy of 5-azacitidine in treating imminent relapse of patients with high-risk MDS or AML and minimal residual disease after allogeneic stem cell transplantation: results of the RELAZA trial
    Platzbecker, U.
    Wermke, M.
    Radke, J.
    Kiani, A.
    Seltmann, F.
    Oelschlaegel, U.
    Roellig, C.
    Mohr, B.
    von Bonin, M.
    Schetelig, J.
    Ehninger, G.
    Bornhaeuser, M.
    Thiede, C.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S79 - S79
  • [48] Immunological Intervention Triggered by Decreasing CD34 + Lineage-Specific Donor Cell Chimerism to Prevent Relapse of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).
    Rosenow, Felix
    Silling, Gerda
    Almut, Berkemeier
    Mueller-Tidow, Carsten
    Koschmieder, Steffen
    Bisping, Guido
    Krug, Utz
    Buechner, Thomas
    Berdel, Wolfgang E.
    Kienast, Joachim
    Stelljes, Matthias
    BLOOD, 2009, 114 (22) : 1286 - 1286
  • [49] 5-AZACITIDINE MAINTENANCE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH HIGH RISK AML AND MDS
    Puglisi, Bruna
    Saraceni, Francesco
    Guerzoni, Selene
    Scortechini, Ilaria
    Mancini, Giorgia
    Fiorentini, Alessandro
    Lotito, Antonio
    Colaneri, Francesca Romana
    Federici, Irene
    Olivieri, Attilio
    BONE MARROW TRANSPLANTATION, 2023, 58 (SUPP1) : 364 - 365
  • [50] Allogeneic HSCT in therapy-associated AML and MDS after treatment for lymphoma: A retrospective single-center analysis
    Wenge, Daniela Vanessa
    Reicherts, Christian
    Mikesch, Jan-Henrik
    Groth, Christoph
    Wethmar, Klaus
    Schliemann, Christoph
    Mesters, Rolf
    Kessler, Torsten
    Khandanpour, Cyrus
    Schmitz, Norbert
    Lenz, Georg
    Stelljes, Matthias
    BONE MARROW TRANSPLANTATION, 2019, 54 : 165 - 166
12345